Kymentie Ferdinande: Rivaroxaban in Cirrhosis and the Path Toward Individualized Anticoagulation
Kymentie Ferdinande, PhD Researcher UNIPD at University of Padova, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“We are pleased to share our Letter to the Editor in Journal of Thrombosis and Haemostasis (JTH) commenting on the recent work by Cindy Pereira Portela, Lorenzo Alberio and colleagues on the effect of direct oral anticoagulants in cirrhosis.
In this letter, we present complementary in vitro data on rivaroxaban in cirrhosis, in line with those of Portela et al.. Together, these observations support the need for more individualized anticoagulation strategies in cirrhosis, an area that warrants further investigation.
Many thanks to the authors for their interesting reply!”
Title: “Effect of direct oral anticoagulants in cirrhosis: an in vitro study”: comment
Authors: Kymentie Ferdinande, Jill Vercruyssen, Jochen Decaestecker, Charlotte De Vloo, Inge Van Haute, Helena Degroote, Sarah Raevens, Xavier Verhelst, Anja Geerts, Hans Van Vlierberghe, Katrien M. J. Devreese
Read the Full Article on Journal of Thrombosis and Hemostasis
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 22, 2026, 15:47Mohammed Alo: Being Fit Does Not Protect You from High LDL
-
Apr 22, 2026, 15:28ASH Committee Brings the Voice of Hematology to Capitol Hill
-
Apr 22, 2026, 15:22Stephen Pendergast: Are Universal Shelf Stable Blood Substitutes Finally Within Reach?
-
Apr 22, 2026, 14:51Mavis Agnes Kisakye: Reconnecting to Drive the Global Bleeding Disorders Agenda Forward
-
Apr 22, 2026, 14:48Augustina Isioma Ikusemoro: Not Every Antigen Speaks Loudly, But the Right Test Will Hear It
-
Apr 22, 2026, 14:47Karuna Kumar: Busting the Myth about Increasing Infection Risk by IV Iron
-
Apr 22, 2026, 14:46David Brown: Charting a New Path Forward for One Patient Facing Extraordinary Cardiac Challenges
-
Apr 22, 2026, 14:45Ney Carter Borges: Syphilis and Cardiovascular Risk – A Silent and Progressive Vascular Burden
-
Apr 22, 2026, 14:44Sanjay Ahuja – New CEO and Medical Director of Innovative Hematology